Colorectal Cancer Chemoprevention by Mesalazine and Its Derivatives
Patients with inflammatory bowel disease (IBD) face an increased lifetime risk of developing colorectal cancer (CRC). Independent factors associated with increased risk include long disease duration, extensive colonic involvement, young age at onset of IBD, severity of inflammation, primary sclerosi...
Main Authors: | Stolfi, Carmine, Pallone, Francesco, Monteleone, Giovanni |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373216/ |
Similar Items
-
Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer
by: Stolfi, Carmine, et al.
Published: (2013) -
Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer
by: Stolfi, Carmine, et al.
Published: (2012) -
Role of TH17 cytokines in the control of colorectal cancer
by: De Simone, Veronica, et al.
Published: (2013) -
The Dual Role of Inflammation in Colon Carcinogenesis
by: Monteleone, Giovanni, et al.
Published: (2012) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
by: Stolfi, Carmine, et al.
Published: (2012)